The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

Frontiers in Oncology

Francesco Pantano¹  Ilaria Portarena²  Rosalina Rossi³  Simone Scagnoli⁴  Andrea Botticelli⁵  Paolo Marchetti⁵  Giuliana D’Auria⁶  Alessio Cirillo⁷  Margherita Muratore⁸  Laura Pizzuti⁹  Eriseld Krasniqi⁹  Michela Roberto^1,10  Eleonora Marrucci^1,12  Agnese Fabbri^1,12  Daniele Alesini^1,13 

[1]0Department of Oncology, University Campus Biomedico of Rome, Rome, Italy

[2]1Medical Oncology Unit, Internal Medicine Department, Tor Vergata Clinical Center University Hospital, Rome, Italy

[3]2Medical Oncology, San Giovanni Addolorata Hospital, Rome, Italy

[4]3Department of Medical and Surgical Sciences and Translational Medicine, “Sapienza” University of Rome, Rome, Italy

[5]Department of Clinical and Molecular Medicine, Sapienza University of Rome, Oncology Unit, Sant’Andrea Hospital, Rome, Italy

[6]Department of Medical Oncology, Sandro Pertini Hospital, Rome, Italy

[7]Department of Radiological, Oncological and Anatomo-Pathological Science, “Sapienza” University of Rome, Rome, Italy

[8]Division of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Roma, Italy

[9]Division of Medical Oncology 2, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute, Rome, Italy

[10]Medical Oncology Unit A, Policlinico Umberto I, Rome, Italy

[11]Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy

[12]Medical Oncology Unit, Belcolle Hospital, Viterbo, Italy

[13]UOSD Centro Oncologico S. Spirito e Nuovo Regina Margherita (SS-NRM), Ospedale Santo Spirito in Sassia, Rome, Italy

关键词: CDK4/6 inhibitor;    oligometastatic;    locally advanced breast cancer (LABC);    ribociclib;    case report;   

DOI  :  10.3389/fonc.2022.797157

来源: DOAJ

【 摘 要 】

The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors to endocrine therapy has remarkably improved the outcome of patients affected with hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2 -) advanced breast cancer (ABC). Ribociclib showed to be effective across most subgroups, regardless of the number and the site of metastasis. Up to 10% of patients with ABC, reported an oligometastatic condition, recently defined as a slow-volume metastatic disease with limited number and size of metastatic lesions (up to 5 and not necessarily in the same organ), potentially amenable for local treatment, aimed at achieving a complete remission status. Despite the wide use of CDK4/6 inhibitors in HR+, HER2-, ABC treatment, data regarding both locally advanced, inoperable disease and oligometastatic conditions are still poor. We reported a review and case series of HR+, HER2-, ABC patients treated with ribociclib as first-line therapy, for a locally advanced and oligometastatic conditions, reporting an impressive response and good safety profile.

【 授权许可】

Unknown